John Rogers Comments on Gilead Sciences Inc.

Guru stock highlight

Author's Avatar
Dec 02, 2015

Biotechnology leader Gilead Sciences, Inc. (NASDAQ:GILD) dropped -15.90% on recent concerns over drug pricing. Gilead actually reported quarterly earnings that were better than expected. We continue to hold the shares, based on our belief that the market is overly focused on pricing and underestimating future sales that we think are likely to grow.

From John Rogers (Trades, Portfolio) 3rd quarter commentary on the Ariel Global Fund.